Alnylam Pharmaceuticals

Alnylam sticks with aggressive litigation strategy against Pfizer and Moderna, filing yet another patent lawsuit
Alnylam sticks with aggressive litigation strategy against Pfizer and Moderna, filing yet another patent lawsuit
Fierce Pharma
Alnylam Pharmaceuticals
legal
patents
vaccines
Pfizer
Moderna Therapeutics
COVID-19
Flag link:
Alnylam’s Onpattro succeeds in open-label ATTR cardiomyopathy extension
Alnylam’s Onpattro succeeds in open-label ATTR cardiomyopathy extension
Clinical Trials Arena
Alnylam Pharmaceuticals
Onpattro
clinical trials
transthyretin amyloidosis with cardiomyopathy
Flag link:
Biotech heads towards big catalysts
Biotech heads towards big catalysts
EP Vantage
biotech
clinical trials
Alnylam Pharmaceuticals
Arcus Biosciences
Argenx
Arrowhead Pharmaceuticals
Axsome Therapeutics
Bavarian Nordic
FibroGen
Gilead Sciences
Incyte
Morphic Therapeutic
PTC Therapeutics
Syndax Pharmaceuticals
Travere Therapeutics
Vaxcyte
Flag link:
Brace for an end-of-year boost to drug approvals
Brace for an end-of-year boost to drug approvals
EP Vantage
FDA
drug approvals
Alnylam Pharmaceuticals
Apellis Pharmaceuticals
Bristol Myers Squibb
Eli Lilly
Gilead Sciences
Mirati Therapeutics
Moderna Therapeutics
Provention Bio
Roche
TG Therapeutics
Travere Therapeutics
Flag link:
Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
Businesswire
Alnylam Pharmaceuticals
clinical trials
cemdisiran
Regeneron
IgAN
immunoglobultin A nephropathy
RNAi
Flag link:
11 drugs granted FDA fast track designation in 2022
11 drugs granted FDA fast track designation in 2022
Beckers Hospital Review
FDA
fast track
Agios Pharmaceuticals
CTI BioPharma
Bristol Myers Squibb
Nobel Biocare
BioXcel Therapeutics
Mycovia Pharmaceuticals
Phathom Pharmaceuticals
Mitsubishi Tanabe Pharma
SIGA technologies
Alnylam Pharmaceuticals
Flag link:
3 Biopharmas on Buyout Watch
3 Biopharmas on Buyout Watch
Motley Fool
M&A
Axsome Therapeutics
Alnylam Pharmaceuticals
Karuna Therapeutics
Flag link:
Drugmakers leap back into fading heart drug market
Drugmakers leap back into fading heart drug market
Beckers Hospital Review
Bristol Myers Squibb
Novartis
Merck
Alnylam Pharmaceuticals
Amgen
hypertension
cholesterol
Flag link:
Alnylam sues Pfizer, Moderna over patent used in mRNA COVID vaccines
Alnylam sues Pfizer, Moderna over patent used in mRNA COVID vaccines
Seeking Alpha
Alnylam Pharmaceuticals
patents
COVID-19
vaccines
Pfizer
Moderna Therapeutics
MRNA
Flag link:
Novartis turns to Alnylam in research deal aimed at liver failure
Novartis turns to Alnylam in research deal aimed at liver failure
BioPharma Dive
Novartis
Alnylam Pharmaceuticals
liver failure
Flag link:
Biopharma developments over the Christmas period
Biopharma developments over the Christmas period
EP Vantage
Alnylam Pharmaceuticals
Bio-Thera Solutions
BioArctic
Biogen
BridgeBio Pharma
Daiichi Sankyo
Eisai
JNJ
Madrigal Pharmaceuticals
Merck
Sutro BioPharma
Tasly Pharmaceutical Group
Flag link: